Clinical Trials Search
A Phase III, Open-label, Randomized Study of Osimertinib with or without Platinum Plus Pemetrexed Chemotherapy, as First-line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA2)
The reason for the study is to find out if an experimental combination of an oral medication called osimertinib (TAGRISSO®) when used in combination with chemotherapy is more effective than giving osimertinib alone for the treatment of locally advanced or metastatic non-small cell lung cancer.
Primary- To evaluate the safety and tolerability of osimertinib plus chemotherapy Secondary : To assess the efficacy of osimertinib plus chemotherapy - To assess the PK of osimertinib when given with chemotherapy
AZD9291 (Osimertinib); Alimta (Pemetrexed); Osimertinib (); Paraplatin (carboplatin); Pemetrexed (); carboplatin (); cisplatin ()